MX2013001870A - Formulaciones oftalmicas de escualamina. - Google Patents
Formulaciones oftalmicas de escualamina.Info
- Publication number
- MX2013001870A MX2013001870A MX2013001870A MX2013001870A MX2013001870A MX 2013001870 A MX2013001870 A MX 2013001870A MX 2013001870 A MX2013001870 A MX 2013001870A MX 2013001870 A MX2013001870 A MX 2013001870A MX 2013001870 A MX2013001870 A MX 2013001870A
- Authority
- MX
- Mexico
- Prior art keywords
- neovascularization
- squalamine
- retinal
- ophthalmic formulations
- macular degeneration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se relaciona con formulaciones oftálmicas de escualamina o sus sales farmacéuticamente aceptables para el tratamiento de condiciones del ojo, tales como por ejemplo degeneración macular húmeda relacionada con la edad (AMD húmeda), neovascularización coroidea, retinopatía, degeneración macular seca relacionada con la edad (AMD seca), vasculopatía coroidea polipoidea, neovascularización después de cirugía ocular, edema macular, obstrucción venosa retiniana, neovascularización subcoroidal, desprendimiento epitelial retiniano, pterigión o atrofia foveal geográfica del epitelio de pigmento retiniano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37452410P | 2010-08-17 | 2010-08-17 | |
PCT/US2011/047920 WO2012024298A1 (en) | 2010-08-17 | 2011-08-16 | Ophthalmic formulations of squalamine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013001870A true MX2013001870A (es) | 2013-07-03 |
Family
ID=44533189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013001870A MX2013001870A (es) | 2010-08-17 | 2011-08-16 | Formulaciones oftalmicas de escualamina. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20130281420A1 (es) |
EP (1) | EP2605752A1 (es) |
JP (2) | JP5956992B2 (es) |
KR (1) | KR101845107B1 (es) |
CN (2) | CN103209683B (es) |
AU (1) | AU2011292160B2 (es) |
CA (1) | CA2808628A1 (es) |
MX (1) | MX2013001870A (es) |
WO (1) | WO2012024298A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
IL282504B (en) * | 2014-09-17 | 2022-08-01 | Panoptica Inc | Ocular formulations for drug administration and protection of the front part of the eye |
AR106691A1 (es) * | 2015-11-13 | 2018-02-07 | Ohr Pharmaceutical Inc | Formulaciones oftálmicas de escualamina |
TW201720446A (zh) * | 2015-11-13 | 2017-06-16 | Ohr製藥公司 | 非典型脈絡膜新生血管(cnv)之大小做為以角鯊胺治療之預測子 |
KR20180036580A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물 |
WO2018185788A1 (en) * | 2017-04-07 | 2018-10-11 | Sun Pharma Advanced Research Company Limited | Ophthalmic solution of bimatoprost |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0444778A1 (en) * | 1990-02-14 | 1991-09-04 | Alcon Laboratories, Inc. | Use of alkyl saccharides to enhance the penetration of drugs |
US5631004A (en) * | 1993-09-30 | 1997-05-20 | Alcon Laboratories, Inc. | Use of sustained release antibiotic compositions in ophthalmic surgical procedures |
WO1997026888A1 (en) | 1996-01-26 | 1997-07-31 | Alcon Laboratories, Inc. | Use of squalamine and its analogues in ophthalmic compositions |
US6262283B1 (en) | 1996-12-06 | 2001-07-17 | Magainin Pharmaceuticals Inc. | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
WO2006082588A2 (en) * | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
CA2814247C (en) * | 2005-04-25 | 2016-01-19 | Genaera Corporation | Polymorphic and amorphous salt forms of squalamine dilactate |
WO2006119211A2 (en) * | 2005-05-02 | 2006-11-09 | Genaera Corporation | Methods and compositions for treating ocular disorders |
AU2006270035A1 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
NZ568313A (en) * | 2005-11-21 | 2011-11-25 | Schering Plough Ltd | Pharmaceutical compositions comprising buprenorphine |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
WO2008031113A2 (en) * | 2006-09-08 | 2008-03-13 | Genaera Corporation | Improved method for inhibition of neovascularization |
GB0625844D0 (en) * | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
-
2011
- 2011-08-16 AU AU2011292160A patent/AU2011292160B2/en not_active Ceased
- 2011-08-16 CN CN201180047840.8A patent/CN103209683B/zh not_active Expired - Fee Related
- 2011-08-16 MX MX2013001870A patent/MX2013001870A/es unknown
- 2011-08-16 CA CA2808628A patent/CA2808628A1/en not_active Abandoned
- 2011-08-16 US US13/817,306 patent/US20130281420A1/en not_active Abandoned
- 2011-08-16 WO PCT/US2011/047920 patent/WO2012024298A1/en active Application Filing
- 2011-08-16 KR KR1020137006746A patent/KR101845107B1/ko active IP Right Grant
- 2011-08-16 EP EP11749654.7A patent/EP2605752A1/en not_active Withdrawn
- 2011-08-16 CN CN201610553185.8A patent/CN106074362A/zh active Pending
- 2011-08-16 JP JP2013524928A patent/JP5956992B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-13 US US14/825,492 patent/US20150342874A1/en not_active Abandoned
-
2016
- 2016-06-17 JP JP2016120681A patent/JP6214726B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2605752A1 (en) | 2013-06-26 |
CN103209683A (zh) | 2013-07-17 |
WO2012024298A1 (en) | 2012-02-23 |
AU2011292160A1 (en) | 2013-03-14 |
JP6214726B2 (ja) | 2017-10-18 |
CA2808628A1 (en) | 2012-02-23 |
CN103209683B (zh) | 2016-08-31 |
JP2016166250A (ja) | 2016-09-15 |
AU2011292160B2 (en) | 2015-09-03 |
US20150342874A1 (en) | 2015-12-03 |
US20130281420A1 (en) | 2013-10-24 |
KR20140021505A (ko) | 2014-02-20 |
JP5956992B2 (ja) | 2016-07-27 |
JP2013537551A (ja) | 2013-10-03 |
CN106074362A (zh) | 2016-11-09 |
KR101845107B1 (ko) | 2018-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY176514A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
MX347226B (es) | Tratamiento de enfermedad ocular. | |
MX2013001870A (es) | Formulaciones oftalmicas de escualamina. | |
MX2016009331A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
MX2023003124A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
MX2021006092A (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. | |
MX2015001741A (es) | Endoprotesis de collar ocular para tratar estrechamiento del angulo iridocorneo. | |
WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
AU2018218696B2 (en) | Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid | |
IN2014CN03123A (es) | ||
WO2012163827A3 (en) | Ophthalmic preparation comprising a pgf2alpha analogue | |
WO2011137344A3 (en) | Anti-s1p antibody treatment of patients with ocular disease | |
MY178169A (en) | Topical ophthalmic peptide formulation | |
WO2008152507A3 (en) | Compositions and methods for treating ophthalmic disorders | |
AU2018240462A1 (en) | Drugs and compositions for the treatment of ocular disorders | |
MX2019011925A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
RU2010135224A (ru) | Способ хирургического лечения макулярного отека после факоэмульсификации катаракты | |
TW201613596A (en) | Ophthalmic suspension preparation | |
WO2019090010A3 (en) | Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma | |
MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
WO2012105854A3 (en) | Compositions for administration to the eye | |
EP3970751C0 (en) | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF CORNEAL EDEMA | |
WO2019083171A3 (ko) | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |